Medivir AB (MVIR B)(製薬・医療分野):企業M&A動向

◆英語タイトル:Medivir AB (MVIR B) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:GDPH61609D
◆発行会社(調査会社):GlobalData
◆発行日:2015年3月25日
◆ページ数:42
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:スウェーデン
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD500 ⇒換算¥55,000見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD750 ⇒換算¥82,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary

Medivir AB (Medivir) is a bio-pharmaceutical company. The company concentrates on the research and development of drugs for the treatment of infectious diseases. It provides drugs for the disorders such as hepatitis C, mouth ulcers, zinc deficiency, psychiatry, HIV, bone disorders, and neuropathic pain. The company’s focus in research and development is on infectious diseases, osteoarthritis, neuropathic pain and oncology. Medvir is headquartered in Stockholm, Sweden.

Medivir AB (MVIR B) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Medivir AB, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 6
Medivir AB, Pharmaceuticals & Healthcare Deals By Type, 2009 to YTD 2015 7
Medivir AB, Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 8
Medivir AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 9
Medivir AB, Pharmaceuticals & Healthcare, Deals Summary, 2009 to YTD 2015 10
Medivir AB, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Medivir Acquires Preclinical Research Stage Assets From Novadex Pharma 12
Partnerships 13
Beactica Enters into Drug Discovery Agreement with Medivir 13
Medivir Enters Into Agreement With Swedish University of Agricultural Sciences To Develop Novel Drugs For Bacterial Infections 14
Medivir Enters Into Distribution Agreement With Daewoong Pharma For Xerclear 15
Medivir Enters Into Collaboration With Janssen Pharmaceutica 16
Medivir Enters Into Distribution Agreement With Daewoong Pharma 18
Licensing Agreements 19
Medivir Enters into License Agreement with Boehringer Ingelheim International for Respiratory Syncytial Virus Drug Program 19
Ferrer And Medivir Enter Into Licensing Agreement For Commercialization Of Adasuve 20
Medivir Terminates Licensing Agreement With Daewoong Pharma For MIV-210 21
Meda Amends Licensing Agreement With Medivir For Xerese 22
GlaxoSmithKline Enters Into Licensing Agreement With Medivir 23
Medivir Enters Into Licensing Agreement With Daewoong Pharma 24
Meda Enters Into Licensing Agreement With Medivir 26
Equity Offering 27
Medivir Completes Private Placement Of Shares For US$31 Million 27
Medivir Completes Private Placement Of US$40 Million 28
Medivir Completes Rights Offering Of US$45 Million 30
Asset Transactions 32
Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir 32
Meda Acquires OTC Products From BioPhausia 33
Acquisition 34
Unimedic To Acquire Cross Pharma From Medivir For US$18.6 Million 34
Bluefish Pharma Acquires BMM Pharma From BioPhausia 35
Medivir Completes Acquisition Of BioPhausia For US$95 Million 37
Medivir AB – Key Competitors 39
Key Employees 40
Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42

List of Tables
Medivir AB, Pharmaceuticals & Healthcare, Key Facts, 2014 1
Medivir AB, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 6
Medivir AB, Pharmaceuticals & Healthcare Deals By Type, 2009 to YTD 2015 7
Medivir AB, Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 8
Medivir AB, Deals By Therapy Area, 2009 to YTD 2015 9
Medivir AB, Pharmaceuticals & Healthcare, Deals Summary, 2009 to YTD 2015 10
Medivir Acquires Preclinical Research Stage Assets From Novadex Pharma 12
Beactica Enters into Drug Discovery Agreement with Medivir 13
Medivir Enters Into Agreement With Swedish University of Agricultural Sciences To Develop Novel Drugs For Bacterial Infections 14
Medivir Enters Into Distribution Agreement With Daewoong Pharma For Xerclear 15
Medivir Enters Into Collaboration With Janssen Pharmaceutica 16
Medivir Enters Into Distribution Agreement With Daewoong Pharma 18
Medivir Enters into License Agreement with Boehringer Ingelheim International for Respiratory Syncytial Virus Drug Program 19
Ferrer And Medivir Enter Into Licensing Agreement For Commercialization Of Adasuve 20
Medivir Terminates Licensing Agreement With Daewoong Pharma For MIV-210 21
Meda Amends Licensing Agreement With Medivir For Xerese 22
GlaxoSmithKline Enters Into Licensing Agreement With Medivir 23
Medivir Enters Into Licensing Agreement With Daewoong Pharma 24
Meda Enters Into Licensing Agreement With Medivir 26
Medivir Completes Private Placement Of Shares For US$31 Million 27
Medivir Completes Private Placement Of US$40 Million 28
Medivir Completes Rights Offering Of US$45 Million 30
Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir 32
Meda Acquires OTC Products From BioPhausia 33
Unimedic To Acquire Cross Pharma From Medivir For US$18.6 Million 34
Bluefish Pharma Acquires BMM Pharma From BioPhausia 35
Medivir Completes Acquisition Of BioPhausia For US$95 Million 37
Medivir AB, Key Competitors 39
Medivir AB, Key Employees 40
Medivir AB, Other Locations 41
Medivir AB, Subsidiaries 41

List of Figures
Medivir AB, Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 1
Medivir AB, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 1
Medivir AB, Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 1
Medivir AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 1
Medivir AB, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 6
Medivir AB, Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 7
Medivir AB, Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 8
Medivir AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 9

★調査レポート[Medivir AB (MVIR B)(製薬・医療分野):企業M&A動向] (コード:GDPH61609D)販売に関する免責事項を必ずご確認ください。
★調査レポート[Medivir AB (MVIR B)(製薬・医療分野):企業M&A動向]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆